Literature DB >> 16872810

Cellular therapies in motor neuron diseases.

Mamatha S Nayak1, Yun-Sook Kim, Michelle Goldman, Hans S Keirstead, Douglas A Kerr.   

Abstract

Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are prototypical motor neuron diseases that result in progressive weakness as a result of motor neuron dysfunction and death. Though much work has been done in both diseases to identify the cellular mechanisms of motor neuron dysfunction, once motor neurons have died, one of potential therapies to restore function would be through the use of cellular transplantation. In this review, we discuss potential strategies whereby cellular therapies, including the use of stem cells, neural progenitors and cells engineered to secrete trophic factors, may be used in motor neuron diseases. We review pre-clinical data in rodents with each of these approaches and discuss advances and regulatory issues regarding the use of cellular therapies in human motor neuron diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872810     DOI: 10.1016/j.bbadis.2006.06.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

Review 1.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

2.  Pituitary adenylyl cyclase-activating peptide counteracts hedgehog-dependent motor neuron production in mouse embryonic stem cell cultures.

Authors:  Megumi Hirose; Pawel Niewiadomski; Gary Tse; Gloria C Chi; Hongmei Dong; Alice Lee; Ellen M Carpenter; James A Waschek
Journal:  J Neurosci Res       Date:  2011-06-14       Impact factor: 4.164

Review 3.  Spinal muscular atrophy: mechanisms and therapeutic strategies.

Authors:  Christian L Lorson; Hansjorg Rindt; Monir Shababi
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

4.  Therapeutic developments in spinal muscular atrophy.

Authors:  Douglas M Sproule; Petra Kaufmann
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

5.  Transplanting p75-suppressed bone marrow stromal cells promotes functional behavior in a rat model of spinal cord injury.

Authors:  Houri Edalat; Zahra Hajebrahimi; Vahid Pirhajati; Mansoureh Movahedin; Mahmoud Tavallaei; Mohammad-Reza Soroush; Seyed Javad Mowla
Journal:  Iran Biomed J       Date:  2013

Review 6.  Perspectives on clinical trials in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; John T Kissel; Thomas O Crawford; Mark B Bromberg; Gyula Acsadi; Guy D'Anjou; Kristin J Krosschell; Sandra P Reyna; Mary K Schroth; Charles B Scott; Louise R Simard
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

7.  Mutant SOD1 microglia-generated nitroxidative stress promotes toxicity to human fetal neural stem cell-derived motor neurons through direct damage and noxious interactions with astrocytes.

Authors:  Jason R Thonhoff; Junling Gao; Tiffany J Dunn; Luis Ojeda; Ping Wu
Journal:  Am J Stem Cells       Date:  2011-08-19

8.  Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes.

Authors:  Wilfried Rossoll; Gary J Bassell
Journal:  Results Probl Cell Differ       Date:  2009

Review 9.  Spinal muscular atrophy.

Authors:  Maryam Oskoui; Petra Kaufmann
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 10.  The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions.

Authors:  Alan Regenberg; Debra J H Mathews; David M Blass; Hilary Bok; Joseph T Coyle; Patrick Duggan; Ruth Faden; Julia Finkel; John D Gearhart; Argye Hillis; Ahmet Hoke; Richard Johnson; Michael Johnston; Jeffrey Kahn; Douglas Kerr; Patricia King; Joanne Kurtzberg; S Matthew Liao; John W McDonald; Guy McKhann; Karin B Nelson; Mahendra Rao; Andrew W Siegel; Kirby Smith; Davor Solter; Hongjun Song; Jeremy Sugarman; Angelo Vescovi; Wise Young; Henry T Greely; Richard J Traystman
Journal:  J Cereb Blood Flow Metab       Date:  2008-08-27       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.